Masato Terashima

1.1k total citations
35 papers, 844 citations indexed

About

Masato Terashima is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Masato Terashima has authored 35 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Masato Terashima's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Mechanisms and Therapy (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Masato Terashima is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Mechanisms and Therapy (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Masato Terashima collaborates with scholars based in Japan and United States. Masato Terashima's co-authors include Kazuto Nishio, Yosuke Togashi, Marco A. De Velasco, Kazuko Sakai, Hidetoshi Hayashi, Yoshihiko Fujita, Shuta Tomida, Kazuhiko Nakagawa, Tetsuya Mitsudomi and Eri Banno and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Masato Terashima

34 papers receiving 833 citations

Peers

Masato Terashima

ONCOL

PRM

PFM

Akihiko Miyanaga Japan

Qunling Zhang China

Qiang Zuo China

Ana Sebio Spain

Audrey Rasmussen United States

Xuenong Ouyang China

Yongping Xu China

Liuxin Cai China

Laura M. Rosenberg United States

Akihiko Miyanaga Japan

Masato Terashima

638 ×1.4

446 ×1.1

ONCOL

426 ×1.2

PRM

295 ×1.4

83 ×0.7

PFM

Citations per year, relative to Masato Terashima Masato Terashima (= 1×) peers Akihiko Miyanaga

Countries citing papers authored by Masato Terashima

Since Specialization

Citations

This map shows the geographic impact of Masato Terashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masato Terashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masato Terashima more than expected).

Fields of papers citing papers by Masato Terashima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masato Terashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masato Terashima. The network helps show where Masato Terashima may publish in the future.

Co-authorship network of co-authors of Masato Terashima

This figure shows the co-authorship network connecting the top 25 collaborators of Masato Terashima. A scholar is included among the top collaborators of Masato Terashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masato Terashima. Masato Terashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Terashima, Masato, et al.. (2025). Preconditioning Effects of Neuromuscular Electrical Stimulation in Patients with Symptomatic Peripheral Arterial Disease. Journal of Atherosclerosis and Thrombosis. 32(8). 1027–1037.

Terashima, Masato, et al.. (2023). Long-Term Tailor-Made Exercise Intervention Reduces the Risk of Developing Cardiovascular Diseases and All-Cause Mortality in Patients with Diabetic Kidney Disease. Journal of Clinical Medicine. 12(2). 691–691. 2 indexed citations

Terashima, Masato, et al.. (2021). Effects of whole-body neuromuscular electrical stimulation device on hemodynamics, arrhythmia, and sublingual microcirculation. Heart and Vessels. 36(6). 844–852. 6 indexed citations

Chiba, Masato, Yosuke Togashi, Yoshihisa Kobayashi, et al.. (2017). Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer. 17(1). 281–281. 29 indexed citations

Banno, Eri, Yosuke Togashi, Marco A. De Velasco, et al.. (2017). Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology. 50(6). 2049–2058. 14 indexed citations

Matsuoka, Hiromichi, Junji Tsurutani, Yasutaka Chiba, et al.. (2017). Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study). BMC Cancer. 17(1). 674–674. 8 indexed citations

Nakamura, Yu, Yosuke Togashi, Hirokazu Nakahara, et al.. (2016). Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. Molecular Cancer Therapeutics. 15(8). 1988–1997. 13 indexed citations

Terashima, Masato, Yosuke Togashi, Katsuaki Sato, et al.. (2016). Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2. Clinical Cancer Research. 22(14). 3663–3671. 15 indexed citations

Sakai, Kazuko, Junji Tsurutani, Takeharu Yamanaka, et al.. (2015). Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS ONE. 10(5). e0121891–e0121891. 30 indexed citations

10.

Togashi, Yosuke, Hidetoshi Hayashi, Kunio Okamoto, et al.. (2015). Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal. Lung Cancer. 88(1). 16–23. 28 indexed citations

11.

Sakai, Kazuko, Azusa Yoneshige, Akihiko Ito, et al.. (2015). Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. SpringerPlus. 4(1). 7–7. 9 indexed citations

12.

Takeda, Masayuki, Kazuko Sakai, Masato Terashima, et al.. (2015). Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Annals of Oncology. 26(12). 2477–2482. 62 indexed citations

13.

Mizukami, Takuro, Yosuke Togashi, Shunsuke Sogabe, et al.. (2015). EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. International Journal of Oncology. 47(2). 499–505. 12 indexed citations

14.

Togashi, Yosuke, Hiroshi Mizuuchi, Shuta Tomida, et al.. (2015). MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer. 90(3). 590–597. 38 indexed citations

15.

Sogabe, Shunsuke, Yosuke Togashi, Hiroaki Kato, et al.. (2014). MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations. Molecular Cancer Therapeutics. 13(12). 3098–3106. 16 indexed citations

16.

Togashi, Yosuke, Hidetoshi Hayashi, Masato Terashima, et al.. (2014). Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation. Journal of Thoracic Oncology. 10(1). 93–101. 43 indexed citations

17.

Togashi, Yosuke, Hiroki Sakamoto, Hidetoshi Hayashi, et al.. (2014). Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters. 356(2). 819–827. 66 indexed citations

18.

Togashi, Yosuke, Hidetoshi Hayashi, Eri Banno, et al.. (2014). Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. International Journal of Oncology. 46(3). 1025–1030. 40 indexed citations

19.

Togashi, Yosuke, Hidetoshi Hayashi, Shunsuke Sogabe, et al.. (2014). Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. International Journal of Oncology. 45(4). 1430–1436. 49 indexed citations

20.

Terashima, Masato, Kazuko Sakai, Yosuke Togashi, et al.. (2014). Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. SpringerPlus. 3(1). 417–417. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact